Shukra Pharmaceuticals has allotted 11.73 lakh equity shares to its promoter, Navkar Surgical Gujarat Limited, following the exercise of share warrants. The company collected Rs 3.13 crore through this conversion, raising its total paid-up capital. While this tranche is complete, investors should note that 17.35 lakh warrants remain outstanding, which could lead to further equity dilution if converted within the stipulated 18-month window.
Shukra Pharmaceuticals Completes Equity Allotment to Promoters
Shares Allotted: 11,73,000 | Capital Inflow: Rs 3.13 Crore
Reader Takeaway: Promoter stake increases through warrant conversion, but shareholders should monitor potential future dilution from remaining 17.35 lakh warrants.
What just happened
Shukra Pharmaceuticals Ltd held a board meeting on September 2, 2026, approving the allotment of 11,73,000 equity shares to Navkar Surgical Gujarat Limited, a promoter group entity. This move follows the exercise of conversion rights on previously issued share warrants. The company successfully collected the balance 75% exercise price of Rs 26.67 per warrant, amounting to a total infusion of Rs 3.13 crore. Consequently, the company's paid-up equity capital has moved from Rs 43.96 crore to Rs 44.08 crore.
The backstory
In January 2026, the company had originally allotted a total of 46,43,000 warrants. Since that issuance, investors and promoters have been progressively exercising their conversion rights. Prior to this current event, 29,08,000 warrants had already been converted into equity. The current allotment represents the latest step in this capital conversion exercise.
What changes now
Existing shareholders should note that the newly allotted shares rank pari passu with current equity, meaning they hold equal rights in terms of dividends and voting. The primary change is the shift in the company's shareholding structure due to the promoter's increased equity position and the corresponding rise in paid-up share capital.
Risks to watch
The primary risk for minority shareholders remains the potential for equity dilution. With 17,35,000 warrants still outstanding, their future conversion—which must occur within 18 months from the initial January 2026 issuance date—will increase the total share count, potentially impacting Earnings Per Share (EPS) metrics.
What to track next
Investors should monitor future exchange filings for any further notices regarding the conversion of the remaining 17.35 lakh warrants. Any update on the utilization of the Rs 3.13 crore capital inflow will also provide clarity on the company's growth strategy.